S. salivarius K12 and M18: The Probiotic Strains That Actually Target Bad Breath

Most discussions of oral probiotics treat all strains as interchangeable. They’re not. The bacteria that help with gut health are fundamentally different from the ones relevant to oral health, and even within oral probiotics, the evidence varies enormously by strain. Two strains have accumulated a genuine body of clinical evidence specifically for bad breath: Streptococcus salivarius K12 and Streptococcus salivarius M18.

Here’s what the science actually shows — and why the combination matters.

What S. salivarius K12 Does

Streptococcus salivarius K12 is a naturally occurring oral bacterium — it’s found in the mouths of people who don’t have bad breath, often in high concentrations. The K12 strain was isolated from a child with no history of sore throats or oral malodor, and it was selected for study because of its unusually potent production of bacteriocin-like inhibitory substances (BLIS).

Bacteriocins are antimicrobial proteins produced by bacteria to inhibit competing species. K12 specifically produces BLIS K12 (salivaricin A2 and salivaricin B), which are active against a range of anaerobic bacteria — including many of the species most responsible for bad breath and tonsil odor.

The mechanism is competitive exclusion with an active antimicrobial component: K12 colonizes the posterior tongue and oropharynx, occupying the ecological niche that VSC-producing anaerobes need, while simultaneously releasing proteins that inhibit their growth.

The Clinical Evidence for K12

Several independent clinical trials have tested K12 specifically for bad breath:

The original Burton et al. trial (2006) compared K12 lozenges with placebo in a small controlled trial. Participants using K12 showed significant reductions in organoleptic breath scores compared to baseline and to placebo. This was the study that established K12 as a viable probiotic approach for halitosis.

The orthodontic appliance study examined K12 in adolescents with fixed orthodontic appliances — a population where bacterial accumulation is high and bad breath is a common complaint. K12 supplementation significantly reduced VSC-producing bacterial counts compared to a control group.

Chlorhexidine comparison: A study comparing K12 with chlorhexidine mouthwash (one of the most potent antibacterial rinses available) found that K12 produced comparable improvements in breath scores. Given that chlorhexidine is the clinical benchmark for oral bacterial suppression, this is a meaningful result.

The consistent finding across trials: K12 reduces organoleptic breath scores and, where measured, VSC levels, with effects that emerge over 1–4 weeks of consistent use.

What S. salivarius M18 Adds

M18 is a sister strain of K12 — also a Streptococcus salivarius isolate, but with a different bacteriocin profile. While K12 is primarily associated with throat and tonsil colonization and BLIS-mediated suppression of anaerobes, M18 focuses its activity at the gingival level.

M18 produces BLIS M18 (salivaricin 9 and salivaricin MPS), which specifically inhibit Streptococcus mutans — the primary bacterial species responsible for tooth decay. It also produces an enzyme (urease) that helps neutralize acidic conditions in dental plaque, reducing the environment that cavity-causing bacteria need.

For bad breath specifically, M18’s contribution is indirect but meaningful. Elevated S. mutans and acidic plaque conditions correlate with elevated overall oral bacterial load, including anaerobes. By suppressing the cavity-causing ecosystem, M18 helps create a less favorable environment for the full range of odor-producing bacteria.

Clinical studies on M18 have shown reductions in S. mutans counts and plaque scores. The combination of K12 (targeting anaerobic VSC producers directly) and M18 (targeting the broader bacterial ecosystem and cavity risk) is theoretically superior to either strain alone.

Why the Combination Matters for Bad Breath

K12 and M18 work on different targets:

• K12 suppresses the specific anaerobes producing VSCs, primarily in the tongue and throat region
• M18 addresses the broader oral ecosystem, reducing the conditions that support pathogen growth

The two strains don’t overlap significantly in their mechanism — they’re complementary. A probiotic containing both covers more ground than one containing only K12, which is why most of the leading single-strain products leave something on the table.

The additional Lactobacillus strains in the Bristle formula (L. reuteri, L. salivarius, L. plantarum) provide additional competitive exclusion and have been studied for oral health benefits independently, though with less bad-breath-specific evidence than K12 and M18.

How to Use These Strains Effectively

Oral probiotics work differently from gut probiotics. The bacteria need to colonize oral surfaces — the posterior tongue and oropharynx — rather than passing through the digestive tract. This means:

• Form matters: lozenges that dissolve slowly in the mouth are the right format. Capsules swallowed whole send the bacteria to the gut before they can colonize the mouth.
• Consistency matters: colonization takes time. Most studies show effects emerging at 1–4 weeks with daily use. Stopping use allows the original microbiome to reassert itself.
• Timing matters: taking the lozenge before bed (after brushing) maximizes contact time with oral surfaces during the overnight period when saliva flow is lowest and the bacteria can colonize without disruption.